1086377-48-1
Chemical Structure
CX1739
- CAS No.: 1086377-48-1
- Formula:C13H15N3O3
- Molecular Weight:261.28
InChIKey: IRYRMRDDVXULFG-UHFFFAOYSA-N
SMILES: O=C(C1=CC2=NON=C2C=C1)N(C)C3CCOCC3
Biological Activity: CX1739 is an orally active, blood-brain barrier permeable, low-efficacy AMPA-glutamate receptor (AMPAR) potentiator. CX1739 enhances excitatory neurotransmission by potentiating glutamate-induced excitatory currents and promoting in vivo long-term potentiation. CX1739 eliminates amphetamine-induced locomotor activity, reverses opioid-, pentobarbital- and ethanol-induced respiratory depression, and exerts pro-cognitive effects in animals. CX1739 impairs motor function recovery and increases the risk of post-injury complications. CX1739 can be used in research related to attention-deficit/hyperactivity disorder, dementia, respiratory depression and spinal cord injury[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CX1739 | 99.63% | CX1739 is an orally active, blood-brain barrier permeable, low-efficacy AMPA-glutamate receptor (AMPAR) potentiator. CX1739 enhances excitatory neurotransmission by potentiating glutamate-induced excitatory currents and promoting in vivo long-term potentiation. CX1739 eliminates amphetamine-induced locomotor activity, reverses opioid-, pentobarbital- and ethanol-induced respiratory depression, and exerts pro-cognitive effects in animals. CX1739 impairs motor function recovery and increases the risk of post-injury complications. CX1739 can be used in research related to attention-deficit/hyperactivity disorder, dementia, respiratory depression and spinal cord injury. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Radin, D.P., et al. Low-Impact Ampakine CX1739 Exerts Pro-Cognitive Effects and Reverses Opiate-Induced Respiratory Depression in Rodents. Future Pharmacol. 2024, 4, 173-187.
- [2]. Xiao D, et al. The impact and mechanism of ampakine CX1739 on protection against respiratory depression in rats. Future Med Chem. 2020;12(23):2093-2104. [Content Brief]
- [3]. Fusco AF, et al. Acute Administration of Ampakine CX1739 after Cervical Spinal Cord Injury. J Neurotrauma. Published online October 6, 2025. [Content Brief]
